Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 Billion
Sandoz announced it has completed the acquisition of Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.5 billion.
Sandoz announced it has completed the acquisition of Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.525 billion in an all-cash transaction. According to a company press release, the acquisition will complement Sandoz’s existing pipeline of biosimilars and generic injectables, ophthalmics, and antibiotics. Sandoz plans to use its global reach to expand Fougera’s dermatology portfolio into new markets.
Currently, Fougera Pharmaceuticals employs approximately 700 people across its US sites. It operates two main businesses: Fougera, specializing in dermatology development and manufacturing, with expertise in the area of semi-solid forms such as creams and ointments, and PharmaDerm, a branded specialty pharma business.
Fougera will be integrated into Sandoz’s US business based in Princeton, New Jersey, but will continue to exist as a separate legal entity. Fougera’s site in Melville, New York, will be home to a new center of excellence for generic dermatology development and manufacturing within the global Sandoz network.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
